Welcome to our dedicated page for ASTRAZENECA PLC SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASTRAZENECA PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASTRAZENECA PLC's regulatory disclosures and financial reporting.
AstraZeneca PLC has admitted 45,750 new ordinary shares of $0.25 each to trading on the London Stock Exchange’s Main Market. These shares were issued between 20 January 2026 and 19 March 2026 under the company’s existing block admission.
The new shares arise from AstraZeneca’s employee share schemes, meaning they were created to satisfy staff share awards or options. Following this admission, the total number of AstraZeneca ordinary shares in issue is 1,550,980,332, all fully fungible with the existing stock.
ASTRAZENECA PLC officer Mani Sharma filed an initial insider ownership report, listing current equity and award holdings in the company. Sharma directly holds 31,153.4659 ordinary shares, plus equity awards that may convert into additional shares over time.
The filing shows 2,996.3080 restricted stock units, each representing a right to receive one ordinary share that vests on November 16, 2028, with shares to be delivered on November 17, 2028. There are also 31.2970 dividend equivalent rights, which accrue on these RSUs and convert into ordinary shares on the same vesting date.
In addition, Sharma holds an employee stock option covering 195 ordinary shares at an exercise price of $123.9800 per share, exercisable from December 1, 2028 until June 1, 2029. The exercise price is originally denominated at GBP93.64, with the reported dollar value based on a stated exchange rate.
AstraZeneca PLC reports that its immunotherapy Imfinzi (durvalumab), combined with standard FLOT chemotherapy, has been approved in the EU as the first perioperative immunotherapy for adults with resectable Stage II-IVA gastric and gastroesophageal junction cancers. The regimen is given before and after surgery, then continued as Imfinzi alone.
The approval is based on the Phase III MATTERHORN trial, where Imfinzi plus FLOT cut the risk of disease progression, recurrence or death by 29% (event-free survival HR 0.71; p<0.001) versus chemotherapy alone, with higher one- and two-year event-free rates. Final overall survival data showed a 22% reduction in the risk of death (HR 0.78; p=0.021), with an estimated 69% of patients alive at three years compared with 62% on chemotherapy alone. The safety profile and surgery completion rates were similar between arms.
AstraZeneca PLC has published its Notice of Annual General Meeting 2026 and shareholders’ circular and is dispatching them to shareholders. The digitally-enabled AGM will be held on 9 April 2026 at 14:30 (BST).
Shareholders will vote on receiving the 2025 accounts, confirming 2025 interim dividends, appointing KPMG LLP as auditor, re-electing directors, approving the remuneration report, renewing authority for the 2020 Performance Share Plan French appendix, authorising political donations, allotting shares, disapplying pre-emption rights, authorising share buybacks, and reducing the notice period for general meetings. The Notice and related documents are available on AstraZeneca’s website and via the UK National Storage Mechanism.
AstraZeneca PLC reported that Chief Executive Officer Pascal Soriot received ordinary shares following the vesting of a long-term incentive award under the AstraZeneca Performance Share Plan (AZPSP).
The AZPSP award, granted on 5 March 2021 with a three-year performance period and subsequent two-year holding period, vested on its fifth anniversary. Application of the original performance conditions led to 88% of the award vesting and the remainder lapsing. After dividend reinvestment and withholding of shares to cover tax obligations, Soriot acquired 101,495 ordinary shares on 5 March 2026 for nil consideration. For tax purposes, the fair market value at vest was 15,088 pence per share, based on the closing price on the previous trading day.
AstraZeneca PLC reported that share awards granted under its AstraZeneca Deferred Bonus Plan for 2022 performance vested on 4 March 2026 for senior executives. These awards reflect portions of prior annual bonuses that were deferred into ordinary shares and held for a three-year period.
On vesting, Chief Executive Officer Pascal Soriot acquired 14,967 ordinary shares and Chief Financial Officer Aradhana Sarin acquired 4,863 ordinary shares, both for nil consideration. For tax purposes, the fair market value at vest was 14,932 pence per ordinary share, based on the closing price on the last trading day before vesting.
AstraZeneca PLC reported that on 4 March 2026 it granted share awards to its Chief Executive Officer and Chief Financial Officer under the AstraZeneca Deferred Bonus Plan and the AstraZeneca Performance Share Plan.
Pascal Soriot received 13,970 Ordinary Shares under the deferred bonus plan and 89,611 under the performance share plan, at an award price of £152.42 per share. Aradhana Sarin received 5,258 Ordinary Shares under the deferred bonus plan and 37,135 under the performance share plan, also at £152.42 per share.
The deferred bonus awards represent required deferrals of each executive’s 2025 annual bonus into shares and are due to vest after a three-year holding period. The performance share awards are subject to scientific, commercial, financial and sustainability performance measures assessed from 1 January 2026 to 31 December 2028 and then a further two-year holding period, vesting on the fifth anniversary of grant.
AstraZeneca PLC reports the issuance by its subsidiary AstraZeneca Finance LLC of three new U.S. dollar fixed rate note tranches, fully and unconditionally guaranteed by AstraZeneca PLC. These consist of $650,000,000 4.000% notes due 2031, $600,000,000 4.300% notes due 2033, and $750,000,000 4.600% notes due 2036.
The company is furnishing this information so the related underwriting, pricing, officer certificates, and legal opinions can be incorporated into its existing shelf registration statement on Form F-3.